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ABSTRACT
The miR-145-5p, which induces TP53-dependent apoptosis, is down-regulated 
in several tumors, including hepatocellular carcinomas (HCCs), but some HCCs show 
physiological expression of this miR. Here we demonstrate that in HCC cells carrying 
wild-type TP53 the steady activation of the miR-145 signaling selects clones resistant 
to apoptosis via up-regulation of the oncogenic miR-483-3p. Expression of the miR-
145-5p and of the miR-483-3p correlated negatively in non-neoplastic liver (n=41; 
ρ=-0.342, P=0.028), but positively in HCCs (n=21; ρ=0.791, P<0.0001), which we 
hypothesized to be due to impaired glucose metabolism in HCCs versus normal liver. 
In fact, when liver cancer cells were grown in low glucose, miR-145-5p lowered 
miR-483-3p expression, allowing apoptosis, whereas when cells were grown in high 
glucose the levels of miR-483-3p increased, reducing the apoptotic rate. This indicates 
that depending on glucose availability the miR-145-5p has double effects on the miR-
483-3p, either inhibitory or stimulatory. Moreover, resistance to apoptosis in clones 
overexpressing both miR-145-5p and miR-483-3p was abrogated by silencing the 
miR-483-3p. Our data highlight a novel mechanism of resistance to apoptosis in liver 
cancer cells harbouring wild type TP53 and suggest a potential role of miR-145-5p 
and miR-483-3p as druggable targets in a subset of HCCs.
INTRODUCTION
The miR-145-5p is deregulated in several tumors 
[1-6]. The tumor suppressor actions of miR-145-5p 
comprise inhibition of cell growth and metastasis [7-9], 
induction of apoptosis [10] and repression of pluripotency 
in embryonic stem cell [11]. These actions depend on 
the fact that miR-145-5p targets several genes relevant to 
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these processes, some of which, such as MDM2, linked 
to the TP53 pathway [9, 11-15]. TP53 is a transcriptional 
activator of the miR-145-5p, is implicated in the miR 
maturation complex and is positively regulated by the 
miR-145-5p [10, 13, 15, 16]. Thus the tumor-suppressor 
activity of the miR-145-5p is linked to the TP53 
mutational/expression status [10, 16, 17].
Hepatocellular carcinoma (HCC), third most 
common cause of cancer-related mortality worldwide 
[18, 19], is associated with several chromosomal, genetic 
and epigenetic aberrations [3, 25-35]. Mutations in the 
TP53 cover only around 20% of all HCCs [20]. On the 
other hand lipid and glucose metabolisms are impaired 
in all HCCs [21-23] and HCC risk is associated with 
viral infections and/or metabolic disorders that promote 
glycolysis/lipogenesis [24].
In 50% of HCCs the miR-145-5p is down-regulated 
[25]. Here we show that in those HCCs with physiologic 
expression of the miRNA, the resistance to the pro-
apoptotic miR-145/TP53 signaling depends on the over-
expression of the miR-483-3p, which targets BBC3/PUMA 
[26]. Thus miR-483-3p could be a crucial suppressor of 
miR-145/TP53 signaling in the HCCs with functional TP53.
RESULTS
The miR-145-5p induces cell growth inhibition 
and cell death by enhancing TP53 activity in 
HepG2 cells
The miR-145-5p has been involved in pro-apoptotic 
signaling through TP53-dependent mechanisms [3, 10, 
15, 27-29]. Here, to confirm this mechanism in liver 
cancer cells, we studied the effects of the enforced expres-
sion of miR-145-5p in HepG2 cells, a TP53 wild type 
hepatoblastoma cell line. Following cell transfection, we 
found that miR-145-5p induces a significant cell growth 
inhibition (p<0.05) after 72 hours (Figure 1A–1B).
In HepG2 cells we confirmed the link between the 
miR-145-5p and the TP53 pathway. Enforced expression 
of the miR-145-5p determined increased luciferase activity 
of the pP53-TA-luc, a TP53 responsive reporter vector 
(p<0001; Figure 1C) together with augmented mRNA 
levels of two TP53 downstream targets, CDKN1A and 
BBC3 (Figure 1D). Moreover, silencing of TP53 could 
partially rescue the effects of miR-145-5p on cell viability 
(Figure 1E)
Figure 1: The miR-145-5p inhibits HepG2 cell growth by activating TP53. A. Growth kinetics of HepG2 cells transiently 
transfected with either miR-145-5p precursor or scramble sequence (NC2) or vehicle of transfection (Lipofectamine). B. Cell 
morphology of HepG2 cells at 72 hours after transfection with either miR-145-5p or NC2. C. TP53 dependent transcriptional activity 
measured by the TP53 responsive luciferase reporter vector, pP53-TA-luc, in HepG2 transfected with either miR-145-5p or NC2 or 
an expression vector carrying the human wild type TP53 cDNA (P53). Firefly luciferase activity was normalized on Renilla luciferase 
acitivity generated by the co-transfected vector pRL-TK. D. CDKN1A and BBC3 expression by RT-qPCR and E. Luminescent cell 
viability assay of HepG2 cells treated (48 hours) with miR-145-5p alone or in combination with siRNA against TP53 (*: p<0.05; **: 
p<0.01; ***: p<0.001; ****: p<0.0001).
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The miR-483-3p protects HepG2 cells from 
miR-145-induced cell death by targeting 
BBC3/PUMA
To study the anti-tumor effects induced by the miR-
145-5p in a subset of HCCs showing its physiological 
expression, we generated stable HepG2 cell clones 
carrying either the miR-145-5p or the control vector. 
Selection yielded hundreds of clones for the control 
vector but only 2 viable clones for the miR-145 (H8 and 
H9) (Figure 2A), suggesting that these clones developed 
resistance to the miR-145-5p constitutive expression. 
To identify potential interplay amongst miRNAs, we 
performed miRNA profiling on RNA from HepG2 cells 
and HepG2 H9 clone. We included in the microarray 
analysis cells with high expression of the miR-145-5p 
determined by either exogenous expression of TP53 or 
MDM2 silencing or Nutlin-3a treatment (Supplementary 
Figure S1). The analysis revealed 6 up-regulated miRNAs, 
with the miR-483-3p in the top list (Figure 2B). In the 
H9 clone the miR-483-3p exhibited a 10-fold increased 
expression compared to HepG2 cells. We recently reported 
the oncogenic activity of miR-483-3p due, at least in 
part, to its target PUMA [26]. Therefore we evaluated 
protein and mRNA levels of PUMA in the H8 and H9 
clones. Both clones exhibited increased levels of BBC3 
mRNA (Figure 2C), but reduced levels of PUMA protein 
compared to HepG2 cells (Figure 2D).
Figure 2: The miR-483-3p expression is induced in HepG2 stable clones over-expressing miR-145-5p. A. ThemiR-145-5p 
expression was evaluated by RT-qPCR in HepG2-miR-145 stable cell clones H8 and H9, in comparison to wild type cells and to miR-
145 transiently transfected cells. H8 and H9 clones exhibited a 1.5-12 fold increase of miR-145-5p expression, compared to wild-type 
cells. B. Heatmap representation of the miRNAs increased in miR-145-5p over-expressing cells assessed using microRNA microarray. 
Fold-change analysis revealed an increased expression of 6 microRNAs both in HepG2 cells with an activated TP53 (PC53SN, siRNA 
anti-MDM2 and Nutlin-3) and HepG2 cells over-expressing miR-145 (miR-145 H9 stable clone) compared to HepG2 cells. C. PUMA 
expression was evaluated by RT-qPCR and D. by Western Blot in H8 and H9 cell clones in comparison to HepG2 cells. Nutlin-3A-treated-
HepG2 cells were used as positive control in quantitative PCR analysis. PUMA expression levels were normalized according to β-actin 
expression in the same samples (*: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001).
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To assess the role of miR-483-3p in cell protection, 
we transfected HepG2 cells with miR-145-5p together 
with an anti-miR-483-3p oligonucleotide. The combination 
resulted in increased cell growth inhibition (p<0.002) 
(Figure 3A). We also inhibited miR-483-3p expression 
by LNA oligonucleotide in the H9 clone. This treatment 
reduced cell growth up to 40% at 72 hours (p<0.0001) 
(Figure 3B), caused an increase of PUMA expression 
(Figure 3C), and induced caspase 3/7 activity (Figure 3D). 
A key role of PUMA was confirmed by a specific siBBC3, 
which abrogated the induction of caspase activity after 
the inhibition of miR-483-3p (Supplementary Figure S2). 
These results support the hypothesis that the miR-483-3p 
confers resistance to TP53-dependent apoptosis in HepG2 
cells over-expressing the miR-145-5p.
To validate these data in another liver cancer in 
vitro model we looked at the expression of the miR-483-
3p in liver cancer cell lines harbouring either wild type 
(Huh-6) or mutant (SNU-449) or null (Hep3B) TP53 
(Supplementary Figure S3A). We chose the HCC Hep3B 
cell line because of the higher expression of the miR-483-
3p (Supplementary Figure S3A). Since they are TP53 null 
we reestablished wild type TP53 protein expression and 
functional activity by the pc53SN vector (Supplementary 
Figure S3B). In this model PUMA was not regulated by 
exogenous TP53 (Supplementary Figure S3B) but still 
targeted by miR-483-3p (Supplementary Figure S3C). 
AMO-483 was able to further increase the PUMA levels 
in presence of TP53 protein (Supplementary Figure 
S3C), the caspase 3/7 activity followed the same trend 
(Supplementary Figure S3D). The effect of the miR-483-
3p in Hep3B cells TP53 null could be imputable to the 
regulation of PUMA by the TP73 protein instead of the 
TP53 (TP53 family: TP53, TP63 and TP73) [30-32].
To further validate the hypothesis that miR-483-3p 
protects from apoptosis in a system in which the miR-
145/TP53 signaling acts properly, we used SNU-449 
cellular model that harbour a mutant form of TP53 (Sanger 
Cosmic Database) and a very low expression of the miR-
483-3p (Supplementary Figure S3A). We registered 
no differences between the caspase activity of cells 
transfected with either the miR-483-3p or the control and 
even an induction when those cells were co-transfected 
with the pc53SN vector (Supplementary Figure S4).
The miR-145-5p/miR-483-3p circuitry is lost 
in HCCs
We searched for an association between miR-145-5p 
and miR-483-3p also in primary HCCs and non-neoplastic 
liver. We analyzed the expression of miR-145-5p and 
miR-483-3p on 41 RNA samples from non-neoplastic 
(NN) hepatic tissue, 40 cirrhotic liver samples (CL) and 
1 normal liver (NL) (Supplementary Table S1); a weak 
but significant negative correlation between the expression 
of the two miRNAs was detected (ρ=-0.342, P=0.028; 
Figure 4A). Since enforced expression of the miR-483-3p 
abrogated the TP53/miR-145 pro-apoptotic loop in HepG2 
cells, we searched for evidence of such mechanism in 
primary HCCs. By analyzing RNA samples from 21 HCC, 
we found a strong positive correlation between the levels 
of the two miRNAs (ρ=0.793, P<0.0001; Figure 4B), 
which supports the hypothesis that high levels of the 
oncogenic miR-483-3p counterbalance high expression 
of the pro-apoptotic miR-145-5p and that in normal cells 
there is a negative feedback loop between miR-145-5p and 
miR-483-3p that is lost in tumor cells.
To strengthen our data, we evaluated the spearman 
correlation factors in other studies that reported 
miRNA profiling in HCC and NN liver (ArrayExpress: 
E-GEOD-30297; E-TABM-866) [33, 34]. In Pineau’ 
study the correlation factor is negative in both NN liver 
(CL, n=90; NL, n=21) and HCC (n=104), but less strong 
in HCC than in NN liver (CL, ρ=-0.55, P<0.0001; HCC, 
ρ=-0.31, P:0.0013)(Supplementary Figure S5A, S5B), 
whereas the data from Barry et al. confirmed the loss of 
the negative correlation between miR-145-5p and miR-
483-3p typical of NN liver (Figure 4A; Supplementary 
Figure S5A), by showing a positive correlation in their set 
of HCC sample (n=97; ρ:-0.025, P=0.8) (Supplementary 
Figure S5C). In vivo studies were conducted by Wang 
et al., who performed hepatic microRNAs profiling at very 
early stages of hepatocarcinogenesis induced by choline-
deficient and amino acid-defined diet (CDAA) in C57BL/6 
mice [35]. We analyzed this dataset for the expression of 
the mmu-miR-145 and mmu-miR-483* in five mice for 
each diet group at each time point (6, 18, 32 and 65 weeks) 
and we identified a negatively correlated expression of the 
two miRNAs in the control group (CSAA) at all time-
points, that was dampened in the CDAA treated group 
(Supplementary Figure S6).
TP53/miR-145-5p signaling rules miR-483-3p 
expression and cell death dependent on the 
glucose concentration of the medium
Next we investigated the events that could invert 
the correlation between the expression of miR-483-3p 
and miR-145-5p in HCC cells. Given that miR-145-5p 
acts as an inhibitor of cellular glucose uptake in HepG2 
[36] and that miR-483-3p is regulated by cellular glucose 
availability (A.V. unpublished dataset), we investigated if 
glucose could modulate the effects of the miR-145-5p on 
the miR-483-3p. We transfected HepG2 cells with miR-
145-5p mimic in either low (1 g/L) or high glucose (4.5 
g/L) DMEM. MiR-145-5p induced down regulation of 
miR-483-3p under low-glucose and up-regulation under 
high-glucose conditions (Figure 5A). This mechanism 
was independent of IGF2 expression since it showed an 
opposite trend of regulation when compared to the miR-
483-3p mature expression (Supplementary Figure S7A, 
S7B). This suggests that glucose availability affects the 
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Figure 3: The miR-483-3p protects miR-145-5p induced cell death by targeting BBC3. A. Growth kinetics of HepG2 cells 
transiently transfected with either miR-145-5p precursor or and LNA-483-3p or scramble sequence (NC2) or vehicle of transfection 
(Lipofectamine). B. Cell viability by inverted microscope analysis and luminescent cell viability assay of H9 HepG2 stable clone transfected 
as described in A). C. BBC3 protein (PUMA) expression by western blot of the H8 and H9 HepG2 stable clones and HepG2 wild type cell 
line. Protein loaded was normalized by measuring the β-actin expression. Densitometric analysis is indicated. D. caspase 3/7 activity of the 
H9 stable clone transiently transfected with either LNA-483-3p or LNA scramble sequence (CTRL) (*: p<0.05; **: p<0.01; ***: p<0.001; 
****: p<0.0001).
Figure 4: miR-145-5p/miR-483-3p correlations in non-neoplastic liver and hepatocellular carcinoma. The miR-145-5p 
and miR-483-3p expressions obtained by microarray analysis or RT-qPCR were evaluated in A. non-neoplastic liver samples (NT) and B. 
hepatocellular carcinomas (HCC) respectively. Spearman correlation (ρ) and correlation p value (p) are indicated.
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regulation of the miR-483-3p by the miR-145-5p. The 
same results were obtained in Hep3B cells in which we 
restored the TP53 protein expression (Supplementary 
Figure S8A, S8B). Next we hypothesized that HepG2 
cells cultured in high-glucose could overcome the 
tumor suppressive effects of miR-145-5p through the 
up-regulation of miR-483-3p. To verify this hypothesis 
we quantified the apoptotic HepG2 cells after transient 
transfection with miR-145-5p under either low or high 
glucose conditions. As expected, miR-145-5p induced 
apoptosis in low glucose, as shown by the increase in 
Annexin V-stained HepG2 cells (32.5% vs 43.4%), 
whereas in high-glucose the miR-145-5p decreased the 
number of apoptotic cells (57.9% vs 48.1%) (Figure 5B 
upper panel). We obtained similar results with Propidium 
Iodide (PI) staining (Figure 5B lower panel).
Since we showed that miR-145-5p is able to induce 
TP53 activity, we tested its effect on TP53 protein levels 
by western blot. Cells with higher expression of the miR-
145-5p revealed increased TP53 protein levels under 
both low and high glucose (low: +143%; high: +33%, 
compared to the NC1 transfections), but PUMA, target 
of the miR-483-3p, increased only in low-glucose (Figure 
5C). This is in line with the evidence that miR-483-3p 
expression is lowered by miR-145-5p in low-glucose 
and increased in high-glucose (Figure 5A). To further 
support these results we indirectly induced miR-145-
5p expression by activating TP53 using Nutlin-3a, an 
inhibitor of the E3 ubiquitin-protein ligase MDM2, 
under both low and high glucose. As expected, caspase 
3/7 activity was slightly increased only in low glucose 
(Figure 5D). Induced expression of the miR-145-5p after 
transfection and Nutlin-3a treatment and consequent 
regulation of miR-483-3p were measured by RT-qPCR 
(Supplementary Figure S7A, S7C, S7D).
Our data show how miR-145/TP53/PUMA 
signaling induces apoptosis only in HepG2 cells cultured 
in a low–glucose; however miR-145-5p exerts a growth 
inhibitory effect also in high glucose, as shown in Figure 
1 and 3. Since PUMA contributes to autophagy [37] we 
hypothesized that autophagy could be activated by the 
miR-145-5p/miR-483-3p regulation in HepG2 cells. 
By measuring the GFP-LC3-II accumulation at the 
autophagosomal membranes we found that miR-145-5p 
was able to induce autophagy in HepG2 cells under both 
low and high glucose (Supplementary Figure S9A–S9B). 
Next we investigated the effect of the miR-145-5p on cell 
cycle regulation. We analyzed the protein levels of p21 
and p27 after enforced expression of miR-145-5p under 
both glucose conditions. The p21 and p27 proteins were 
induced by miR-145-5p ectopic expression only in HepG2 
cells cultured in high glucose (Figure 5E, Supplementary 
Figure S9C). Overall these data suggest that the miR-145-
5p is able to induce apoptosis in HepG2 cells cultured in 
low glucose, while it only slows down the cell cycle under 
high glucose.
Stable activation of TP53 through Nutlin-3a 
selects HepG2 clones with impaired miR-483/
miR-145 ratio
Finally, we used Nutlin-3a (2.5 μM) under low-
glucose to constitutively activate TP53 and induce 
resistance of HepG2 cells to death. After 30 days we 
counted five clones in HepG2 cells treated with Nutlin-
3a. These clones were picked up and maintained in low 
glucose conditions for a few days; during such period 
only one (clone 4, cl.4) survived. After that, we re-
established Nutlin-3a until the 65th day. At the same time, 
as a reference experiment, we treated HepG2 cells with 
Nutlin-3a at two concentrations (2.5 and 5 μM) for a 4 
days period, sampling the RNA every day. To achieve 
comparability between the two experiments and determine 
the interplay between miR-483-3p and miR-145-5p, we 
took in consideration the ratio of the relative expressions of 
these two miRNAs (miR-483/miR-145) (Figure 6A). The 
HepG2 cl.4 between 50 and 65 days showed significant 
increases in the miR-483-3p/miR-145-5p ratio (Figure 6A, 
right side), contrary to what we observed after short term 
exposure to Nutlin-3a (Figure 6A, left side), that resulted 
a decrease of the miR-483-3p/miR-145-5p ratio. Our 
data demonstrate the ability of miR-483-3p to elude the 
miR-145/TP53 signaling, suggesting that this microRNA 
selects HCC cells that show a physiologic miR-145/TP53 
signaling to nullify the tumor suppressive actions. To 
support this conclusion, we performed a meta-analysis 
correlating TP53 mutational status with miR-483-3p and 
miR-145-5p expression in 193 HCC samples from the 
TCGA dataset (http://firebrowse.org) (TP53 Mut: 60; 
TP53 Wt: 133). The miR-145-5p showed no difference in 
expression between the two groups (Figure 6C), whereas, 
as expected, the miR-483-3p was significantly up regulated 
in the TP53 Wt HCCs when compared to those harboring 
TP53-mutations (Figure 6B).
DISCUSSION
The expression of the miR-145-5p is generally down-
regulated in HCC and correlated to tumor grade (Edmondos 
grade) [3, 27], but it is not uncommon to find HCCs that 
show normal expression of the miR-145-5p. We relied 
on HepG2 cell clones stably expressing miR-145-5p to 
investigate the possible processes of resistance to cell death 
induced by TP53/miR-145-5p signaling in this particular 
HCC subset. These HepG2 clones showed up-regulation of 
5 microRNAs related to TP53 activity: miR-483-3p, miR-
197, miR-768-5p, mir-940 and miR-630. Interestingly 4 out 
of these 5 deregulated miRNAs are involved in resistance 
to apoptosis: miR-483-3p is known to target BBC3/PUMA 
in HCC and CRC [26, 38]; miR-197 is deregulated in lung 
cancers harbouring wild type TP53 [39]; miR-940 and miR-
630 are up-regulated in cisplatin-resistant lung and head and 
neck cancers [40-42]. We focused on the most significantly 
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up-regulated miRNA, the miR-483-3p. We demonstrated 
that the over-expression of miR-483-3p is an important 
factor to overcome the pro-apoptotic effects of miR-145-
5p. We also identified a negative correlation between the 
miR-145-5p and the miR-483-3p in non-neoplastic liver that 
became less evident, lost or positive in HCCs. This suggests 
the presence of a regulative loop between these two 
microRNAs: in physiological conditions miR-145/TP53 
signaling results in the inhibition of miR-483-3p (negative 
correlation), whereas in neoplastic conditions miR-145-5p 
selects cells that show higher expression of miR-483-3p 
(positive correlation). The expression and activity of the 
miR-145-5p is associated to TP53 [10, 15, 16] whereas miR-
483-3p is correlated to β–catenin nuclear activity [38]. Since 
Figure 5: Glucose media concentrations rule the miR-145-5p effects on HepG2 cells. A. miR-483-3p relative expression by 
RT-qPCR normalized on RNU44 in HepG2 cells transfected with either miR-145-5p or negative control miR (NC1); cells were grown in 
either low (LowGlc) or high (HighGlc) glucose concentration (1 g/L and 4.5 g/L respectively). B. Flow cytometry analysis of annexin-V 
(upper panel) and propidium iodide (bottom panel) staining apoptotic/dead HepG2 cells following transfection with either miR-145-5p or 
control (NC1) grown for 72h in different glucose concentrations. C. TP53 and PUMA/BBC3 protein relative concentration by Western 
blot in HepG2 cells treated as described in B). D. Caspase 3/7 activity in HepG2 cells transfected with miR-145-5p or control (NC1) in low 
and high glucose concentration. E. P21 (upper panel) and P27 (bottom panel) relative protein concentration normalized on β actin protein 
expression by Western blot in HepG2 cells blocked with thymidine for 17 hours and transfected with miR-145-5p (red triangles) or control 
NC1 (green squares) in low glucose and high glucose at 0, 3, 8 and 20 hours. In the graphs of RT-qPCR and Caspase 3/7 activity the data 
are represented by the means and standard deviations of technical and experimental replicates. Student t test was used for the statistical 
analysis (*: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001).
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mutations in TP53 and β–catenin are mutually exclusive 
in HCC [20], we speculate that the HCCs that show TP53 
mutations, and consequent down regulation of PUMA, p21 
and other TP53 targets, do not need the up-regulation of 
miR-483-3p to reduce the apoptotic rate. On the contrary, 
as confirmed by our data, the HCCs with wild-type TP53 
select cells with higher expression of the miR-483-3p. We 
found that, on the basis of glucose availability, the miR-145-
5p represses (low glucose) or induces (high glucose) the 
expression of the miR-483-3p. We propose that increased 
glucose uptake in the progression from pre-neoplastic to 
neoplastic liver cells and the metabolic shift from aerobic to 
anaerobic metabolism (Warburg’s effect), typical of cancer 
[43, 44], affect the physiologically negative regulation of 
miR-483-3p and the miR-145/TP53 axis, dampening the 
anti-tumoral effect of this pathway and facilitating tumor 
development. Thus, to exclude resistance via miR-483-3p 
upregulation, the possible therapeutic development of miR-
145-5p mimics should comprise strategies directed also to 
the concurrent inhibition of the miR-483-3p.
MATERIALS AND METHODS
Cell lines and in vitro assays
Hepatoblastoma (HepG2, Huh-6) and hepatocarcinoma 
(Hep3B, SNU-449) cell lines are from ATCC (UK). HepG2 
cells harbour a wild type TP53 gene, while Hep3B are null 
Figure 6: miR-145-5p and miR-483-3p expressions related to TP53 activity and mutational status. A. Long treatment 
with Nutlin-3a selects HepG2 cells with high miR-483-3p/miR-145-5p expressions rate. miR-483-3p/miR-145-5p relative expressions rate 
of HepG2 treated with Nutlin-3a (2.5 μM and 5 μM) and vehicle (CTRL) during four days of treatment (left side). On the right side of 
the graph is represented the miR-483-3p/miR-145-5p relative expressions rate of the HepG2 stable clone 4 (HepG2 Cl.4) after 51 and 60 
days of treatment with Nutlin-3a. Expression level of miR-483-3p B. and miR-145-5p C. in 199 HCC samples with (n=60) or without 
(n=133) mutations in TP53 gene. The expression of miR-483-3p is significantly higher (p 0.01 at two-sided t-test) in TP53 WT than TP53 
mutated HCC. The results shown here are based upon miRseq_mature_preprocess data generated by the TCGA Research Network: http://
cancergenome.nih.gov/ and downloaded from FireBrowse portal (*: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001).
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for the TP53 gene (www-p53.iarc.fr). They were cultured 
in IMEM/DMEM supplemented with 10% fetal calf serum. 
For in vitro cell growth assays, cells were seeded in 24-well 
plates at a density of 70,000cells/well. The transfection was 
performed by Lipofectamine2000 protocol (Invitrogen, CA, 
USA) with a final concentration of 100 nM for either miR-
145 precursor or negative control molecule (Ambion negative 
control #2). Four replicates of each condition were counted at 
each time point (0, 24, 48 and 72 hours). Time 0 was the time 
of transfection. siRNA-PUMA (Dharmacon) and siRNA-p53 
(Dharmacon) were transfected at final concentration of 100 
nM. To test the effect of Nutlin-3a on miR-145 expression, we 
treated cells for 48 hours at a final concentration of 5 μM. The 
number of cells was counted using hemocytometer chamber. 
Cell viability was analyzed by using CellTiter- GloTM 
Luminescent Cell Viability Assay (Promega, WI, USA), and, 
apoptosis by using Caspase- Glo™ 3/7 Assay (Promega, WI, 
USA)
MicroRNA precursor molecules and siRNAs
Synthetic microRNA precursor molecules and negative 
controls (Ambion negative control #2) were purchased form 
Ambion (Austin, TX). The synthetic oligos were dissolved in 
nuclease free water to a stock concentration of 50μM. Small 
interfering RNA (siRNA) against TP53 and PUMA were 
purchased from Dharmacon (Thermo Scientific, MA, USA). 
Anti-miR-483-3p LNA oligonucleotide was purchased from 
Exiqon (Vedbaek, Denmark).
TP53 expression and reporter vectors
The reporter vector pp53-TA-Luc (Clontech 
Carlsbad, CA, USA) was used to quantify TP53 
transcriptional activity. The vector contains a TP53 
responsive element located upstream the TATA box from 
the herpes simplex virus timidine kinase promoter (pTA). 
Downstream of pTA is the firefly luciferase reporter gene 
(Luc). The pRL-TK vector contains the herpes simplex 
virus thymidine kinase promoter to provide low to 
moderate levels of Renilla luciferase expression in co-
transfected mammalian cells. The vector was used as an 
internal control reporter in combination with pp53-TA-Luc 
reporter vector. Luciferase activity was measured using a 
dual luciferase kit (Promega, WI, USA) and quantified 
at a luminometer (Turner, Biosystems, Sunnyvale, CA, 
USA). Each condition was assayed in four replicates in 
two independent experiments. The TP53 mammalian 
expression vectors pc53SN, which carries a human wild 
type TP53 cDNA were a kind gift of Dr. Arnold Levine 
and were previously described [45].
RNA isolation, retrotranscription and 
quantitative PCR
The RNA purification by Trizol was performed 
according to manufaturer’s indications (Invitrogen, 
Carlsband, CA, USA). For mature microRNA 
quantification we performed a Taqman Real time PCR, 
using miR-145-5p, miR-483-3p, RNU6B and RNU44 
probes (Applied Biosystems, Foster City, CA). 25 ng 
of total RNA was retrotranscribed using the specific 
stemloop primers. For BBC3/PUMA, CDKN1A/p21 and 
TP53 and quantification we used Taqman assays from 
Applied Biosystems (Foster City, CA). IGF2 expression 
were quantified by using UPL technology (Roche) (UPL: 
#40; U40_IGF2_F: acaccctccagttcgtctgt; U40_IGF2_R: 
gaaacagcactcctcaacga). First, 0.5-1 ug of total RNA 
was retrotranscribed by SuperScript II (Invitrogen, 
Carlsband, CA, USA) with random hexamers; then, PCR 
amplification was performed using Taqman primers and 
probes as indicated by manufacturer (Applied Biosystems, 
Foster City, CA). microRNAs expressions were 
normalized to RNU6B or RNU44 expressions, whereas 
mRNAs were normalized on ACTB expression. The delta 
Ct method was used to calculate the relative abundance.
Western blotting and antibodies
Cells were collected by trypsin-EDTA and dissolved 
in NP40 lysis buffer (0.5% NP40, 250mM NaCl, 
50mM Hepes, 5mM EDTA and 0.5mM EGTA) freshly 
supplemented with Complete inhibitor (Roche, Mannheim, 
Germany) and phosphatase inhibitor cocktail 1&2 (Roche, 
Mannheim, Germany). The following antibodies were 
used for the detection of p53 (polyclonal p53 Antibody 
#9282 Cell Signaling, Danvers, MA, 1:1000), CDKN1A/
p21 (clone CP74, P1484 Sigma-Aldrich, St. Louis, MO, 
1:200), PUMA (polyclonal PUMA Antibody #4976 Cell 
Signaling, Danvers, MA, 1:1000) and β-actin (clone AC-
40, A4700 Sigma Aldrich, St. Louis, MO, 1:1000).
Human microRNA microarray detection 
and data analysis
MiRNA expression was investigated using the 
Agilent Human miRNA microarray v.2 (#G4470B, 
Agilent Technologies). This microarray consists of 
60-mer DNA probes synthesized in situ and contains 
15,000 features which represent 723 human microRNAs, 
sourced from the Sanger miRBASE database (Release 
10.1). One-hundred ngs of total RNA were employed in 
each experiment. RNA labeling and hybridization were 
performed in accordance to manufacturer’s indications. 
Agilent scanner and the Feature Extraction 10.5 
software (Agilent Technologies) were used to obtain the 
microarray rawdata. Microarray results were analyzed 
by using the GeneSpring GX 10 software (Agilent 
Technologies). Data transformation was applied to set 
all the negative raw values at 1.0, followed by a Quantile 
and on-gene median normalization. Fold-change analysis 
was used to identify the microRNAs activated both by 
TP53 (pc53SN, siRNA anti-MDM2 and Nutlin-3a) and 
miR-145-5p (miR-145 H9 stable clone).
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Statistical analysis
The Student’s t test was used to compare average 
values between groups of samples (such as miRNA 
expression data, number of proliferating cells, etc). All 
reported p-values were calculated assuming groups with 
unequal variance.
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